Safety and Tolerability of Oral Proglumide for NASH

Inclusion Criteria: * Male or female subjects ages 18 years to 85 * with radiographic imaging (by ultrasound, MRI, or CT) of fatty liver disease * AND elevation in serum transaminases (ALT or AST). * AND one of the following: BMI\>30, hyperlipidemia, or evidence of poorly controlled diabetes such as HgbA1C \>7 * Subjects on statins and with diabetes are eligible. Statins will be continued at the same dose for the duration of the study. * Evidence of mild to moderate fibrosis on Fibroscan of F1 to F3 (kPa score \< 14). Exclusion Criteria: * Evidence of active alcohol use/abuse. * Chronic viral hepatitis B or hepatitis C, autoimmune hepatitis, drug induced liver disease. * Those with evidence of cirrhosis on exam, histologically, or imaging, and a history of liver cancer are excluded. * Laboratory tests that warrant exclusion include: Leukocyte Count \<3.5 K/UL; Hemoglobin \<9.5 g/dL; Blood Urea Nitrogen \>30 mg/dL (hydrated); Creatinine \>2.0 mg/dL, alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) \> 5X ULN (upper limit normal), alkaline phosphatase (ALP)\>2X ULN. * Evidence of abnormal synthetic liver function including abnormal total bilirubin, platelet count \<150,000 / mm3; and abnormal prothrombin time or increased INR (international normalized ratio) (unless on warfarin) * History of gall bladder disease with gall bladder not surgically removed * Estimated glomerular filtration rate (eGFR of \< 90 mL/min/1.73m2 * Type 1 diabetes mellitus * Poorly controlled diabetes, defined by hemoglobin A1C (HbA1C) \> 8, or diabetic patients that have not been on stable doses of anti-diabetic medication for at least 90 days prior to screening * Pregnant or breast feeding * A known preexisting medical or psychiatric condition that could interfere with the patient's ability to provide informed consent or participate in study conduct, or that may confound the study findings. * Those found to have fibrosis score on Fibroscan of F0 or F4.